

Aram Babcock

Email: arambabcock@ufl.edu

[LinkedIn.com/in/aram-babcock](https://www.linkedin.com/in/aram-babcock)

PERSONAL STATEMENT

Highly capable of using clinical and research skills synergistically to help solve real-world healthcare problems for patients using sound, scientifically based judgments. Strengths include a strong business acumen acquired through years of managerial oversight of pharmacy operations and methodological training for both health economics and outcomes research resulting in several peer-reviewed publications and broad spectrum knowledge base.

PROFESSIONAL EXPERIENCE

- ❖ **Graduate Student Research Assistant** January 2018 - August 2021
College of Pharmacy, University of Florida
- ❖ **Graduate Student Teaching Assistant** August 2017 - August 2021
College of Pharmacy, University of Florida
- ❖ **HEOR Internship** March 2020 – August 2020 (remote)
Hematology/Oncology, Karyopharm Therapeutics, Newton, MA
- ❖ **Pharmacy Manager, Staff, Floater** August 2008-present
Walgreens Co./Walgreens Boots Alliance
- ❖ **Graduate Student Teaching Assistant** September 2015 - May 2017
College of Pharmacy, University of Rhode Island

EDUCATION

- ❖ University of Florida College of Pharmacy Gainesville, FL Anticipated Fall 2021
Doctor of Philosophy (PhD) in Pharmaceutical Sciences
Concentration: Pharmaceutical Outcomes & Policy

Dissertation: *Evaluation of HER2-directed therapies in HER2+ non-metastatic breast cancer in women*
- ❖ University of Rhode Island Kingston, RI August 2017
Master of Sciences (M.S.) in Pharmaceutical Sciences
Concentration: Pharmacoepidemiology and Pharmacoeconomics

Thesis: Babcock, Aram, “Concomitant Use of Central Nervous System Stimulants and Depressants Prescribed in Rhode Island” (2017). *Open Access Master's Theses*. Paper 1054.
<https://digitalcommons.uri.edu/theses/1054>
- ❖ University of Rhode Island Kingston, RI August 2017
Master of Business Administration (MBA)
- ❖ University of Rhode Island Kingston, RI May 2008
Doctor of Pharmacy (PharmD)

PUBLICATIONS

- ❖ **Primary Author**

Aram Babcock

Email: arambabcock@ufl.edu

[LinkedIn.com/in/aram-babcock](https://www.linkedin.com/in/aram-babcock)

- ✚ **Babcock A**, Ali AA, Balkrishnan R, Montero A, Diaby V. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. *J Manag Care Spec Pharm*. 2020;26(7):826-831. doi:10.18553/jmcp.2020.26.7.826. PMID: 32584682.
- ✚ **Babcock A**, Moussa RK, Diaby V. Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates. *Res Social Adm Pharm*. 2020 Sep 8:S1551-7411(20)30838-X. doi: 10.1016/j.sapharm.2020.09.003. Epub ahead of print. PMID: 32928656.
- ✚ **Babcock A**, Moussa RK, Diaby V. Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation [published online ahead of print, 2021 May 3]. *Expert Rev Pharmacoecon Outcomes Res*. 2021;1-12. doi:10.1080/14737167.2021.1914593
- ✚ *Huang Y, ***Babcock A**, Diaby V. A Commentary on the Cost-effectiveness of Next Generation Sequencing. (*Under Review*) * co-first authors.
- ❖ **Contributing Author**
 - ✚ Diaby V, Almutairi RD, **Babcock A**, Moussa RK, Ali A. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. *Expert Rev Pharmacoecon Outcomes Res*. 2020 Dec 1:1-12. doi: 10.1080/14737167.2021.1848553. Epub ahead of print. PMID: 33213205.
 - ✚ Chen Z, **Babcock A**, Sanogo V, Xiao H, Diaby V. Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014 [published online ahead of print, 2021 May 14]. *Expert Rev Pharmacoecon Outcomes Res*. 2021;10.1080/14737167.2021.1927717. doi:10.1080/14737167.2021.1927717
 - ✚ Diaby V, **Babcock A**, Huang Y, Moussa RK, Janvier M, Espinal P, Soler D, Falcon M, Gupta A, Jayakar P, Diaz-Barbosa M, Totapally B, Salyakina D. Is RAPID Whole-Genome Sequencing for Critically ILL Pediatric Patients Cost-Effective? (*Under Review*)

CONFERENCE ABSTRACTS

- ❖ **Babcock A**, Diaby V. Determinants, trends, and costs associated with 30-day all-cause readmission in children, adolescents, and young adults with suicidal ideation using the Nationwide Readmission Database. Paper presented at: Virtual ISPOR Conference, May 18-20, 2020, Orlando, FL, USA.
- ❖ **Babcock A**, Moussa R, Diaby V. Suicidal Ideation Diagnosis Code Placement and Implications for National Readmissions. Paper presented at: ICPE Annual Conference, August 26-30, 2020, Berlin, DE.
- ❖ Almutairi R, Diaby V, **Babcock A**, Ali AA, Moussa RK. Cost-Effectiveness of Treatments for HER2-Positive Metastatic Breast Cancer and Associated Metastases: An Overview of Systematic Reviews. Paper presented at: Virtual ISPOR Annual Conference, May 17-20, 2021.
- ❖ Diaby V, **Babcock A**, Huang Y, Moussa RK, Janvier M, Espinal P, Soler D, Falcon M, Gupta A, Jayakar P, Diaz-Barbosa M, Totapally B, Salyakina D. Is RAPID Whole-Genome Sequencing for Critically ILL Pediatric Patients Cost-Effective? Paper presented at: Virtual ISPOR Annual Conference, May 17-20, 2021.

Aram Babcock

Email: arambabcock@ufl.edu

[LinkedIn.com/in/aram-babcock](https://www.linkedin.com/in/aram-babcock)

- ❖ Chen Z, **Babcock A**, Sanogo V, Xiao H, Diaby V. Predictors of 30-Day Readmission and Hospitalization Costs of Patients with Hepatic Encephalopathy in the US from 2010 to 2014. Paper presented at: Virtual ISPOR Annual Conference, May 17-20, 2021.

SCHOLARSHIPS/AWARDS

- ❖ PhRMA Foundation Health Equity Challenge Award, 2020
- ❖ DuBow Fellowship, University of Florida, FY 2018-2019
- ❖ Grinter Fellowship, University of Florida
- ❖ Centennial Scholarship, University of Rhode Island, 2002-2008

PROFESSIONAL MEMBERSHIPS

- ❖ International Society for Pharmacoeconomic Outcomes Research (ISPOR) – UF Chapter
- ❖ International Society for Pharmacoepidemiology (ISPE) – UF Chapter

PERSONAL PROFESSIONAL DEVELOPMENT

- ❖ Causal Inference Conference, Rutgers/UPenn (New Brunswick, NJ, July 2019)
- ❖ ISPOR: Short Courses (Boston, MA & New Orleans, LA, May 2019)
 - ✓ Use of Propensity Scores in Observational Studies of Treatment Effects
 - ✓ Using DICE Simulation for Health Economic Analyses
 - ✓ Advanced Decision Modeling for Health Economic Evaluations
 - ✓ Market Access & Value Assessment of Medical Devices
 - ✓ A Health Economics Approach to US Value Assessment Frameworks
- ❖ University of Arizona College of Pharmacy (Tucson, AZ, January 2017)
 - ✓ Certificate of Participation: Advanced Course in Pharmacoeconomic Modeling
- ❖ ISPOR Training Program (RTI, Durham, NC, October 2016)
 - ✓ Learn to build a budget impact model: Budget Impact Analysis Training